{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:21:47Z","timestamp":1790018507316,"version":"4.0.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omton.2026.201143","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:17:14Z","timestamp":1770077834000},"page":"201143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["EpCAM\u2013PSMA: Potential predictors of treatment outcomes for PSMA-targeted alpha therapies in metastatic castration-resistant prostate cancer"],"prefix":"10.1016","volume":"34","author":[{"given":"G\u00e1bor","family":"Bakos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Bauder-W\u00fcst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Landry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Roscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Be\u00e1ta","family":"Ramasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bruchertseifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Kratochwil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edr","family":"Bene\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bene\u0161ov\u00e1-Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201143_bib1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/1874471011666180502104524","article-title":"An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth","volume":"11","author":"Morgenstern","year":"2018","journal-title":"Curr. Radiopharm."},{"key":"10.1016\/j.omton.2026.201143_bib2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/ph17010076","article-title":"Alpha-Emitting Radionuclides: Current Status and Future Perspectives","volume":"17","author":"Miederer","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.omton.2026.201143_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00259-021-05434-9","article-title":"Global experience with PSMA-based alpha therapy in prostate cancer","volume":"49","author":"Sathekge","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.omton.2026.201143_bib4","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/pros.24137","article-title":"(225) Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis","volume":"81","author":"Ballal","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.omton.2026.201143_bib5","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.119.234559","article-title":"Patients Resistant Against PSMA-Targeting alpha-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes","volume":"61","author":"Kratochwil","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.omton.2026.201143_bib6","article-title":"Advancements and Applications of Liquid Biopsies in Oncology: A Narrative Review","volume":"15","author":"Noor","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.omton.2026.201143_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071377","article-title":"The Role of Circulating Tumor Cells as a Liquid Biopsy for Cancer: Advances, Biology, Technical Challenges, and Clinical Relevance","volume":"16","author":"Allen","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201143_bib8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: From the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.omton.2026.201143_bib9","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2967\/jnumed.123.266702","article-title":"Prognostic Performance of RECIP 1.0 Based on [(18)F]PSMA-1007 PET in Prostate Cancer Patients Treated with [(177)Lu]Lu-PSMA I&T","volume":"65","author":"Hartrampf","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.omton.2026.201143_bib10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1089\/bio.2015.0074","article-title":"Cryopreservation of Circulating Tumor Cells for Enumeration and Characterization","volume":"14","author":"Nejlund","year":"2016","journal-title":"Biopreserv. Biobank."},{"key":"10.1016\/j.omton.2026.201143_bib11","doi-asserted-by":"crossref","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-04-0378","article-title":"Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases","volume":"10","author":"Allard","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201143_bib12","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.3390\/cells9081836","article-title":"Epithelial Cell Adhesion Molecule: An Anchor to Isolate Clinically Relevant Circulating Tumor Cells","volume":"9","author":"Eslami-S","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.omton.2026.201143_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/1849454418782617","article-title":"Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin","volume":"7","author":"Po","year":"2018","journal-title":"J. Circ. Biomark."},{"key":"10.1016\/j.omton.2026.201143_bib14","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201143_bib15","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1038\/s41598-018-22594-1","article-title":"PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis","volume":"8","author":"Bravaccini","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2026.201143_bib16","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2967\/jnumed.114.147413","article-title":"Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer","volume":"56","author":"Benesova","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.omton.2026.201143_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231157632","article-title":"Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials","volume":"15","author":"Jang","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.omton.2026.201143_bib18","first-page":"3629","article-title":"Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium","volume":"57","author":"Liu","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201143_bib19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41388-018-0488-5","article-title":"A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome","volume":"38","author":"Stylianou","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.omton.2026.201143_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.162907","article-title":"Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer","volume":"8","author":"Sayar","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.omton.2026.201143_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41698-022-00289-1","article-title":"Identification of epithelial and mesenchymal circulating tumor cells in clonal lineage of an aggressive prostate cancer case","volume":"6","author":"Chai","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.omton.2026.201143_bib22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nprot.2014.006","article-title":"Full-length RNA-seq from single cells using Smart-seq2","volume":"9","author":"Picelli","year":"2014","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omton.2026.201143_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbae243","article-title":"irGSEA: the integration of single-cell rank-based gene set enrichment analysis","volume":"25","author":"Fan","year":"2024","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.omton.2026.201143_bib24","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2026.201143_bib25","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1007\/s00259-023-06340-y","article-title":"Long-term survival outcomes of salvage [(225)Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study","volume":"50","author":"Ballal","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.omton.2026.201143_bib26","doi-asserted-by":"crossref","first-page":"9812","DOI":"10.1038\/s41598-021-88988-w","article-title":"Ubiquitin-mediated DNA damage response is synthetic lethal with G-quadruplex stabilizer CX-5461","volume":"11","author":"Masud","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2026.201143_bib27","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1093\/emboj\/19.13.3388","article-title":"Two RING finger proteins mediate cooperation between ubiquitin-conjugating enzymes in DNA repair","volume":"19","author":"Ulrich","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/j.omton.2026.201143_bib28","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1128\/MCB.00987-08","article-title":"Noncanonical E2 variant-independent function of UBC13 in promoting checkpoint protein assembly","volume":"28","author":"Huen","year":"2008","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omton.2026.201143_bib29","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.molcel.2007.01.029","article-title":"A critical role for the ubiquitin-conjugating enzyme Ubc13 in initiating homologous recombination","volume":"25","author":"Zhao","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omton.2026.201143_bib30","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.cell.2021.01.048","article-title":"RNA polymerase III is required for the repair of DNA double-strand breaks by homologous recombination","volume":"184","author":"Liu","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201143_bib31","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrc2889","article-title":"IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer","volume":"10","author":"Gyrd-Hansen","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2026.201143_bib32","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1007\/PL00000744","article-title":"Structure and function of the type 1 insulin-like growth factor receptor","volume":"57","author":"Adams","year":"2000","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omton.2026.201143_bib33","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/me.2015-1073","article-title":"Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo","volume":"29","author":"Ofer","year":"2015","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.omton.2026.201143_bib34","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.260943","article-title":"Adaptations of membrane trafficking in cancer and tumorigenesis","volume":"137","author":"Evergren","year":"2024","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.omton.2026.201143_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.648384","article-title":"Rab GTPases: Central Coordinators of Membrane Trafficking in Cancer","volume":"9","author":"Jin","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omton.2026.201143_bib36","doi-asserted-by":"crossref","first-page":"15787","DOI":"10.1073\/pnas.1204540109","article-title":"TBC1D16 is a Rab4A GTPase activating protein that regulates receptor recycling and EGF receptor signaling","volume":"109","author":"Goueli","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201143_bib37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s10565-024-09866-5","article-title":"Function and regulation of Rab GTPases in cancers","volume":"40","author":"Xu","year":"2024","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.omton.2026.201143_bib38","first-page":"4950","article-title":"Rab4b controls an early endosome sorting event by interacting with the gamma-subunit of the clathrin adaptor complex 1","volume":"126","author":"Perrin","year":"2013","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.omton.2026.201143_bib39","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1242\/jcs.01168","article-title":"Rab11 regulates the recycling and lysosome targeting of beta2-adrenergic receptors","volume":"117","author":"Moore","year":"2004","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.omton.2026.201143_bib40","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2967\/jnumed.117.203877","article-title":"A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies","volume":"59","author":"O'Keefe","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.omton.2026.201143_bib41","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.jacbts.2023.03.011","article-title":"Biochemical Structure and Function of TRAPP Complexes in the Cardiac System","volume":"8","author":"Papaioannou","year":"2023","journal-title":"JACC. Basic Transl. Sci."},{"key":"10.1016\/j.omton.2026.201143_bib42","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1152\/physiol.00017.2011","article-title":"COPII and COPI traffic at the ER-Golgi interface","volume":"26","author":"Szul","year":"2011","journal-title":"Physiology"},{"key":"10.1016\/j.omton.2026.201143_bib43","doi-asserted-by":"crossref","first-page":"C1319","DOI":"10.1152\/ajpcell.00540.2002","article-title":"Rab5a and rab11a mediate agonist-induced trafficking of protease-activated receptor 2","volume":"284","author":"Roosterman","year":"2003","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.omton.2026.201143_bib44","doi-asserted-by":"crossref","first-page":"37919","DOI":"10.18632\/oncotarget.6114","article-title":"Endosomal gene expression: a new indicator for prostate cancer patient prognosis?","volume":"6","author":"Johnson","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2026.201143_bib45","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/modpathol.2010.208","article-title":"PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events","volume":"24","author":"Agell","year":"2011","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.omton.2026.201143_bib46","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2020.04.058","article-title":"Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer","volume":"78","author":"Herberts","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.omton.2026.201143_bib47","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omton.2026.201143_bib48","doi-asserted-by":"crossref","first-page":"21138","DOI":"10.3390\/ijms160921138","article-title":"PI3K and AKT: Unfaithful Partners in Cancer","volume":"16","author":"Faes","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201143_bib49","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1002\/jcp.24065","article-title":"PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics","volume":"227","author":"Mahajan","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.omton.2026.201143_bib50","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1158\/1078-0432.CCR-23-2161","article-title":"ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature","volume":"30","author":"Vellky","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201143_bib51","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1158\/0008-5472.CAN-18-0430","article-title":"HER2 Amplification in Tumors Activates PI3K\/Akt Signaling Independent of HER3","volume":"78","author":"Ruiz-Saenz","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201143_bib52","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.omton.2026.201143_bib53","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-Targeted alpha-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.omton.2026.201143_bib54","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1534\/g3.117.300257","article-title":"Large-Scale Low-Cost NGS Library Preparation Using a Robust Tn5 Purification and Tagmentation Protocol","volume":"8","author":"Hennig","year":"2018","journal-title":"G3 (Bethesda)"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:23:53Z","timestamp":1778271833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926000196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2950329926000196"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201143","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EpCAM\u2013PSMA: Potential predictors of treatment outcomes for PSMA-targeted alpha therapies in metastatic castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201143"}}